Skip to main content

Colorectal Cancer Clinical Trials

Review the colorectal cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 201-225 of 447

Ulixertinib and Cetuximab or Ulixertinib, Cetuximab, and Encorafenib for the Treatment of Unresectable or Metastatic Colorectal Cancer in Patients Who Have Received EGFR or BRAF-Directed Therapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
TAS-102 and Irinotecan after Surgery for the Treatment of ctDNA Positive, Stage II-III Colorectal Cancer
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Yttrium Y-90 Radioembolization before Surgery for Tumor Control and Future Liver Remnant Hypertrophy Patients with Colorectal Liver Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
Status: Active
Location: 2 locations
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ProAgio with Fluorouracil, Irinotecan, and Bevacizumab for the Treatment of Advanced or Metastatic Colorectal Cancer
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients with Solid Tumor Cancers Being Treated with Standard of Care Checkpoint Inhibitors
Status: Active
Location: 5 locations
Adaptive Radiation Therapy Boost for the Treatment of Rectal Cancer, The ARBOR Trial
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Pooled Mutant KRAS-Targeted Long Peptide Vaccine with Balstilimab and Botensilimab for the Treatment of Patients with Stage IV Non-MSI-H/dMMR Colorectal Cancer and Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Trifluridine/Tipiracil in Combination with Talazoparib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Neoadjuvant Chemotherapy Combined with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, SMART TNT Study
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Chemotherapy with Radiation for the Treatment of Rectal Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Status: Active
Location: 4 locations
A Study of DM001 in Patients With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Status: Active
Location: 2 locations
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas